Last Updated on December 13, 2021 by The Health Master
Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market generic drug Cariprazine capsules, which are used in the treatment of schizophrenia.
The company’s subsidiary has received tentative approval from the US Food and Drug Administration (USFDA) for Cariprazine capsules in the strengths of 1.5 mg, 3 mg, 4.5 mg, and 6 mg, the drug firm said in a statement.
Cariprazine is an atypical antipsychotic medication used for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar disorder.
The drug production will be done at the group’s formulation manufacturing facility in the Special Economic Zone (SEZ), Ahmedabad.
The group now has 325 approvals and has so far filed over 400 ANDAs (Abbreviated New Drug Applications) since the commencement of the filing process in FY 2003-04, the drug maker noted.
Alembic gets USFDA tentative nod for drug for high BP
Biocon gets USFDA nod for Mycophenolic Acid
Morepen gets USFDA nod for anti-allergy drug
USFDA approves new drug to help identify cancer lesions
USFDA grants accelerated approval for Vosoritide for injection
Zydus Cadila gets USFDA nod to market generic Cancer drug in US
High Court quashed the criminal complaint of alleged NSQ drug
Medical treatments may get more expensive for you from next year
Increase in Pharmacy colleges to meet rising demand of Medical Stores
Pharmexcil is seeking candidates for the role of Director
IPC flags safety alert against NSAID Diclofenac
Narcotics Drugs: Team raids Zirakpur Pharmaceuticals firm
Sun Pharma gets CDSCO panel nod for FDC Brinzolamide, Timolol, Pot…
Procedure for registration of Medical Devices: CDSCO
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
